Delivery Order SPE2DB22D2211-SPE2DB24FNBC0

Award Date 3/22/24
Potential Completion Date 3/25/24
Potential Value $1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide Ondansetron ODT 4 mg tablets. The contract has a potential value of $1,664.49 and a period of performance through February 7, 2024. Amerisourcebergen Drug Corp is the prime contractor and this order is issued under a larger indefinite delivery contract (IDC) awarded by DLA with a potential value of $999,999,999.00...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $5,014.40 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the delivery of ondansetron ODT 4 mg tablets. This order is part of a larger indefinite delivery contract (IDC) valued at up to $999,999,999.00, which serves as the primary vehicle for Amerisourcebergen to provide pharmaceutical products and medical supplies to DLA Troop Support Medical facilities supporting the...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the delivery of Ondansetron ODT 4 mg tablets. The order, valued at $3,672.70, has a completion date of February 1, 2024. Amerisourcebergen Drug Corp is the prime contractor and no set-aside designation was used. This delivery order is issued under a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide Ondansetron ODT 4 mg tablets. The contract has a completion date of February 26, 2024 and a potential value of $2,571.12. Amerisourcebergen Drug Corp is the prime contractor and no set-aside designation was used. This award is associated with a larger indefinite delivery contract (IDC) with DLA, valued at up to...
This federal contract award to AmerisourceBergen Drug Corp is a delivery order valued at $46,836.72 from the Defense Logistics Agency (DLA) for the supply of 4,560,650 units of the drug Ondansetron ODT 4 mg tablet. The contract has a period of performance through April 20, 2023, and utilizes a firm fixed price pricing structure. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for providing a...
This is a federal contract award made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999 and running through November 2026. The Delivery Order has a ceiling value of $31,404.78 and provides for the supply of Ondansetron ODT 4 mg Tablets. The contract does...
This federal contract award, valued at $6,699.43, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, the prime contractor, for the delivery of 4,564,128,973 units of Ondansetron ODT 8 mg Tablets. The contract is a firm fixed price delivery order with an ultimate completion date of April 2, 2024. AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distributor AmerisourceBergen Corporation, is the prime contractor on an indefinite delivery...
The U.S. government agency Defense Logistics Agency (DLA) awarded a $12,102.52 Firm Fixed Price Delivery Order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the supply of 4,564,287,347 units of Ondansetron ODT 8 mg Tablets. This contract is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 that Amerisourcebergen holds with DLA Troop Support Medical, which serves as the primary vehicle for the company...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, to provide Ondansetron ODT 4 mg tablets to the U.S. government. The $3,125.70 Delivery Order contract has a firm fixed price and an ultimate completion date of July 5, 2024. Amerisourcebergen, through its Corporate Office Division, has a significant Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 with the DLA to supply a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,707.55 firm fixed price delivery order is for the supply of 4,566,197,426 units of Ondansetron ODT 4 mg tablets. The contract has an ultimate completion date of October 25, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
  • SPE2DB22D2211
    Indefinite Delivery Contract
  • SPE2DB22D2211-SPE2DB24FNBC0
    Delivery Order

This federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distributor Amerisourcebergen Corporation, is for the delivery of Ondansetron ODT 4 mg tablets. The contract is a firm fixed price delivery order with a ceiling value of $1,041.90 and a performance period through March 2024. Amerisourcebergen Drug Corp is also the prime contractor on an indefinite delivery contract (IDC) with DLA, valued at up to $999,999,999.00 through December 2025, which serves as the primary vehicle for the company to provide pharmaceuticals and medical supplies to DLA Troop Support Medical facilities supporting the Department of Defense. This contract award does not have a set-aside designation.

Generated 6/21/24, 9:29 AM